Clinical Trial Update: A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy [Phase 3]

View source ↗

Summary

A Phase 3 randomized, active-controlled study comparing SHR-A1811 to Trastuzumab emtansine (T-DM1) in HER2-positive primary breast cancer with residual invasive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• SHR-A1811
• Trastuzumab emtansine (ado-trastuzumab emtansine)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy | Phase 3 | Status: RECRUITING